Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.

Autor: Stefanska AM; European Medicines Agency, London, UK., Distlerová D; Medicines and Healthcare Products Regulatory Agency, London, UK., Musaus J; European Medicines Agency, London, UK., Olski TM; European Medicines Agency, London, UK., Dunder K; European Medicines Agency, London, UK.; Läkemedelsverket, Medical Products Agency, Uppsala, Sweden., Salmonson T; European Medicines Agency, London, UK.; Läkemedelsverket, Medical Products Agency, Uppsala, Sweden., Mentzer D; European Medicines Agency, London, UK.; Paul-Ehrlich Institut, Langen, Germany., Müller-Berghaus J; European Medicines Agency, London, UK.; Paul-Ehrlich Institut, Langen, Germany., Hemmings R; European Medicines Agency, London, UK.; Medicines and Healthcare Products Regulatory Agency, London, UK., Veselý R; European Medicines Agency, London, UK.

Publikováno v: Archives of disease in childhood [Arch Dis Child] 2017 Oct; Vol. 102 (10), pp. 952-957. Date of Electronic Publication: 2017 May 29.

High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy.

Autor: Hunzelmann N; Department of Dermatology and Venerology, University of Cologne, Cologne, Germany. Nico.Hunzelmann@uni-koeln.de, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Olski TM, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M

Publikováno v: Arthritis research & therapy [Arthritis Res Ther] 2009; Vol. 11 (2), pp. R30. Date of Electronic Publication: 2009 Mar 04.